Drug news
Merck files V 503 at FDA for 9 valent Human Papillomavirus Virus (HPV) vaccine
Merck has announced that the Biologics License Application for V 503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the FDA. V 503 is designed to compete with Gardasil, Merck's own drug. V 503 protects against 9 strains of the HPV virus, compared to four for Gardasil.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins